VY-AADC01: Interim Phase Ib data

Interim data from 10 patients with advanced PD in cohorts 1 and 2 of an open-label, dose-escalation, U.S. Phase Ib

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE